AMPLIFY trial: how prognostic mutations impact outcomes with acalabrutinib-venetoclax in CLL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2026-01-27
Просмотров: 41
Описание:
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses an exploratory analysis of the Phase III AMPLIFY trial (NCT03836261) evaluating how key prognostic mutations impact outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy in chronic lymphocytic leukemia (CLL). Prof. Ghia highlights consistent progression-free survival (PFS) benefits across genetic subgroups and the potential added value of obinutuzumab in overcoming higher-risk features. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
